This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cavacini, L. A.
Right arrow Articles by Posner, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cavacini, L. A.
Right arrow Articles by Posner, M. R.

 Previous Article  |  Next Article 

Journal of Virology, November 1999, p. 9638-9641, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Minimal Incidence of Serum Antibodies Reactive with Intact Primary Isolate Virions in Human Immunodeficiency Virus Type 1-Infected Individuals

Lisa A. Cavacini,1,* J. Elaine Peterson,1 Erica Nappi,1 Mark Duval,1 Robert Goldstein,2 Kenneth Mayer,2,3 and Marshall R. Posner1

Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School,1 and Fenway Community Health Center,2 Boston, Massachusetts, and Department of Medicine and Division of Infectious Diseases, Brown University School of Medicine, Pawtucket Memorial Hospital, Pawtucket, Rhode Island3

Received 14 September 1998/Accepted 9 July 1999

Immunoglobulin G reactive with primary isolate virions was detected in 36% of serum samples from individuals infected with human immunodeficiency virus type 1. Of these individuals, serum samples from only 7% captured significant quantities of virus. Virion-specific antibody correlated with CD4 counts and, of more significance, primary isolate neutralization. Further dissection of this response should lead to the identification of antibodies and antigenic epitopes for vaccine purposes.


* Corresponding author. Mailing address: Beth Israel Deaconess Medical Center, One Deaconess Rd., BL 556, P.O. Box 15709, Boston, MA 02215. Phone: (617) 632-1161. Fax: (617) 632-0181. E-mail: lcavacin{at}caregroup.harvard.edu.


Journal of Virology, November 1999, p. 9638-9641, Vol. 73, No. 11
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Duval, M., Posner, M. R., Cavacini, L. A. (2008). A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils. J. Virol. 82: 4671-4674 [Abstract] [Full Text]  
  • Derby, N. R., Kraft, Z., Kan, E., Crooks, E. T., Barnett, S. W., Srivastava, I. K., Binley, J. M., Stamatatos, L. (2006). Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.. J. Virol. 80: 8745-8762 [Abstract] [Full Text]  
  • Gorny, M. K., Revesz, K., Williams, C., Volsky, B., Louder, M. K., Anyangwe, C. A., Krachmarov, C., Kayman, S. C., Pinter, A., Nadas, A., Nyambi, P. N., Mascola, J. R., Zolla-Pazner, S. (2004). The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. J. Virol. 78: 2394-2404 [Abstract] [Full Text]  
  • Beaumont, T., van Nuenen, A., Broersen, S., Blattner, W. A., Lukashov, V. V., Schuitemaker, H. (2001). Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course. J. Virol. 75: 2246-2252 [Abstract] [Full Text]